Lexaria Bioscience Corp. (LEXX)
NASDAQ: LEXX · Real-Time Price · USD
0.8809
-0.0191 (-2.12%)
At close: Jul 11, 2025, 4:00 PM
0.9000
+0.0191 (2.17%)
After-hours: Jul 11, 2025, 4:32 PM EDT
Lexaria Bioscience Stock Forecast
LEXX's stock price has decreased by -69.52% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Lexaria Bioscience stock has a target of 5, which predicts a 467.6% increase from the current stock price of 0.88.
Price Target: $5 (+467.6%)
Analyst Consensus: Strong Buy
Analyst Ratings
According to 1 stock analyst, the rating for Lexaria Bioscience is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $7 → $5 | Strong Buy | Maintains | $7 → $5 | +467.60% | Jul 1, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 → $7 | Strong Buy | Maintains | $10 → $7 | +694.64% | Jan 24, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +1,035.20% | Dec 2, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +1,035.20% | Nov 25, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +1,035.20% | Jul 18, 2024 |
Financial Forecast
Revenue This Year
492.32K
from 464.28K
Increased by 6.04%
Revenue Next Year
533.46K
from 492.32K
Increased by 8.36%
EPS This Year
-0.64
from -0.47
EPS Next Year
-0.55
from -0.64
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 741,300 | 1.2M | 1.5M | ||
| Avg | 492,323 | 533,460 | 715,530 | ||
| Low | 180,320 | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 59.7% | 149.2% | 176.1% | ||
| Avg | 6.0% | 8.4% | 34.1% | ||
| Low | -61.2% | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.61 | -0.47 | -0.40 |
| Avg | -0.64 | -0.55 | -0.79 |
| Low | -0.66 | -0.67 | -1.15 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.